The Experts below are selected from a list of 10164 Experts worldwide ranked by ideXlab platform
Steven A Kaplan - One of the best experts on this subject based on the ideXlab platform.
-
re twelve week prospective open label randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add on therapy to an Alpha Blocker for lower urinary tract symptoms
The Journal of Urology, 2015Co-Authors: Steven A KaplanAbstract:for this article http://dx.doi.org/10.1016/j.juro.2015.08.038 available at http://jurology.com/ Editorial Comment: Precision medicine is a glossy term that is often used as a goal in delivery of optimal outcomes. Notwithstanding costs and access, this concept is a more achievable goal than in the past. For example in the arena of lower urinary tract symptoms in men the ability to hone in on types of symptoms, ie storage vs voiding, and prostate size can help us to prescribe the most appropriate therapy. With a new cadre of available agents that can address nocturia, overactive bladder symptoms and sexual dysfunction we can more precisely diagnose and treat men with lower urinary tract symptoms. This study tests that hypothesis by using either desmopressin or an anticholinergic agent as an add-on to an Alpha Blocker. The authors found that the addition of desmopressin helped decrease the number of nocturnal episodes, nocturnal urine volume and nocturnal index in men with nocturnal polyuria. Similarly the nocturnal bladder capacity index and urgency episodes decreased in the anticholinergic add-on group. Nocturia is multifactorial and not just related to benign prostatic hyperplasia. Yet we often use classic benign prostatic hyperplasia agents such as Alpha Blockers in an attempt to treat men with nocturia. Studies such as this highlight the need to hone in on what is causing nocturia in an individual, including concomitant disorders such as diabetes, sleep apnea, polydipsia, reduced bladder capacity and polyuria. The take home message is that, as experts in voiding function in men (and women!), we should tailor our therapies to the specific complaint of the patient and take into account prostate size, types of symptoms and causative etiology of nocturia to deliver better health outcomes and more durable and sustainable results. Steven A. Kaplan, MD Suggested Reading Lose G, Mattiasson A, Walter S et al: Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004; 172: 1021.
-
Alpha Blocker therapy current update
Reviews in urology, 2005Co-Authors: Steven A KaplanAbstract:Alpha-Blockade is the predominant form of medical therapy for the treatment of symptomatic bladder outlet obstruction due to benign prostatic hyperplasia (BPH). Recent research has shown that there is a series of Alpha(1) receptor subtypes present in humans and that the Alpha(1A) subtype appears to play a primary role in mediating prostatic smooth muscle contraction. Recent interest has therefore focussed on the development of agents specific to this Alpha(1A) receptor subtype. The approval by the Food and Drug Administration of tamsulosin, an Alpha(1A)-specific antagonist, offers physicians in the United States the opportunity to prescribe a selective Alpha(1)-Blocker for the treatment of BPH. Tamsulosin offers a pharmacologic means to better target Alpha-blockade specifically to the prostatic smooth muscle and spare the vascular smooth muscle. Use of this agent has resulted in a lower incidence of clinically relevant effects on blood pressure or heart rate and minimal cardiovascular adverse effects.
-
intermittent Alpha Blocker therapy in the treatment of men with lower urinary tract symptoms
Urology, 1998Co-Authors: Steven A Kaplan, Rodolfo Borges Dos Reis, Adauto Jose Cologna, Haylton Jorge Suaid, Antonio Carlos Pereira Martins, Ira J KohnAbstract:Abstract Objectives. To determine the safety and efficacy of intermittent Alpha-Blocker therapy in men with lower urinary tract symptoms (LUTS) in a prospective study. Alpha-Blockers have been demonstrated to be safe and effective in the treatment of men with LUTS. To date, the role of varying dosing regimens in responding patients has not been well studied. Methods. Men with LUTS were entered into this prospective open label, parallel, randomized trial. In phase 1, patients were treated with alfuzosin, 2.5 mg three times daily for 3 months. In phase 2, those patients who had a significant therapeutic response were randomized into one of the following three groups: (1) maintenance of alfuzosin; (2) alfuzosin every other day; and (3) discontinuation of alfuzosin (ie, no treatment). Patients were followed up for a total of 6 months. Parameters of evaluation included the International Prostate Symptom Score (IPSS), global satisfaction, peak urinary flow rate (Qmax), and adverse events. Results. At 3 months, there were 79 patients who were categorized as having obtained a therapeutic response: IPSS decreased to 7.6 ± 3.2 and Qmax increased to 11.3 ± 2.9 mL/s. After randomization, IPSS was 7.1 ± 2.9 and 6.5 ± 2.5 for group 1; 6.5 ± 3.2 and 6.7 ± 2.1 for group 2; and 11.4 ± 4.8 and 12.3 ± 4.9 for group 3 at 3 and 6 months, respectively. Qmax was 12.7 ± 4.8 and 11.7 ± 5.2 mL/s for group 1; 12.2 ± 3.9 and 11.9 ± 3.7 mL/s for group 2; and 9.7 ± 2.5 and 9.3 ± 2.1 mL/s for group 3 at 3 and 6 months, respectively. Global satisfaction at 6 months was the same for groups 1 and 2. There were no differences in adverse events among the three groups. Conclusions. In men with LUTS who responded to alfuzosin, changing the dosing regimen from daily to once every other day resulted in similar efficacy and safety at 3 and 6 months. By contrast, complete cessation of alfuzosin resulted in recurrence of both symptoms and impaired urinary flow. These data provide evidence that in responding patients, intermittent Alpha-Blocker therapy may be a reasonable therapeutic regimen. The role of intermittent Alpha-Blocker therapy using other agents, as well as in a large cohort of men with LUTS, remains to be determined.
Philipp Dahm - One of the best experts on this subject based on the ideXlab platform.
-
Alpha-Blockers after shock wave lithotripsy for renal or ureteral stones in adults.
The Cochrane database of systematic reviews, 2020Co-Authors: Makinna Oestreich, Robin W.m. Vernooij, Niranjan J. Sathianathen, Eu Chang Hwang, Gretchen M Kuntz, Alex Koziarz, Charles D. Scales, Philipp DahmAbstract:Background Shock wave lithotripsy (SWL) is a widely used method to treat renal and ureteral stone. It fragments stones into smaller pieces that are then able to pass spontaneously down the ureter and into the bladder. Alpha-Blockers may assist in promoting the passage of stone fragments, but their effectiveness remains uncertain. OBJECTIVES: To assess the effects of Alpha-Blockers as adjuvant medical expulsive therapy plus usual care compared to placebo and usual care or usual care alone in adults undergoing shock wave lithotripsy for renal or ureteral stones. Search methods We performed a comprehensive literature search of the Cochrane Library, the Cochrane Database of Systematic Reviews, MEDLINE, Embase, several clinical trial registries and grey literature for published and unpublished studies irrespective of language. The date of the most recent search was 27 February 2020. Selection criteria We included randomized controlled trials of adults undergoing SWL. Participants in the intervention group had to have received an Alpha-Blocker as adjuvant medical expulsive therapy plus usual care. For the comparator group, we considered studies in which participants received placebo. Data collection and analysis Two review authors independently selected studies for inclusion/exclusion, and performed data abstraction and risk of bias assessment. We conducted meta-analysis for the identified dichotomous and continuous outcomes using RevManWeb according to Cochrane methods using a random-effects model. We judged the certainty of evidence on a per outcome basis using GRADE. Main results We included 40 studies with 4793 participants randomized to usual care and an Alpha-Blocker versus usual care alone. Only four studies were placebo controlled. The mean age of participants was 28.6 to 56.8 years and the mean stone size prior to SWL was 7.1 mm to 13.2 mm. The most widely used Alpha-Blocker was tamsulosin; others were silodosin, doxazosin, terazosin and alfuzosin. Alpha-Blockers may improve clearance of stone fragments after SWL (risk ratio (RR) 1.16, 95% confidence interval (CI) 1.09 to 1.23; I² = 78%; studies = 36; participants = 4084; low certainty evidence). Based on the stone clearance rate of 69.3% observed in the control arm, an Alpha-Blocker may increase stone clearance to 80.4%. This corresponds to 111 more (62 more to 159 more) participants per 1000 clearing their stone fragments. Alpha-Blockers may reduce the need for auxiliary treatments after SWL (RR 0.67, 95% CI 0.45 to 1.00; I² = 16%; studies = 12; participants = 1251; low certainty evidence), but also includes the possibility of no effect. Based on a rate of auxiliary treatments in the usual care arm of 9.7%, Alpha-Blockers may reduce the rate to 6.5%. This corresponds 32 fewer (53 fewer to 0 fewer) participants per 1000 undergoing auxiliary treatments. Alpha-Blockers may reduce major adverse events (RR 0.60, 95% CI 0.46 to 0.80; I² = 0%; studies = 7; participants = 747; low certainty evidence). Major adverse events occurred in 25.8% of participants in the usual care group; Alpha-Blockers would reduce this to 15.5%. This corresponds to 103 fewer (139 fewer to 52 fewer) major adverse events per 1000 with Alpha-Blocker treatment. None of the reported major adverse events appeared drug-related; most were emergency room visits or rehospitalizations. Alpha-Blockers may reduce stone clearance time in days (mean difference (MD) -3.74, 95% CI -5.25 to -2.23; I² = 86%; studies = 14; participants = 1790; low certainty evidence). We found no evidence for the outcome of quality of life. For those outcomes for which we were able to perform subgroup analyses, we found no evidence of interaction with stone location, stone size or type of Alpha-Blocker. We were unable to conduct an analysis by lithotripter type. The results were also largely unchanged when the analyses were limited to placebo controlled studies and those in which participants explicitly only received a single SWL session. Authors' conclusions Based on low certainty evidence, adjuvant Alpha-Blocker therapy following SWL in addition to usual care may result in improved stone clearance, less need for auxiliary treatments, fewer major adverse events and a reduced stone clearance time compared to usual care alone. We did not find evidence for quality of life. The low certainty of evidence means that our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
-
desmopressin for treating nocturia in men
Cochrane Database of Systematic Reviews, 2017Co-Authors: Jae Hung Jung, Caitlin J Bakker, Mark H Ebell, Philipp DahmAbstract:Background Nocturia is the bothersome symptom of awakening one or more times per night to void. Desmopressin is a commonly used medication for treating nocturia. Objectives To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. Search methods We performed a comprehensive search of medical literature with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017. Selection criteria We included randomized or quasi-randomized trials. Inclusion criteria were men with nocturia defined as one or more voids per night. Trials of children, adults with primary or secondary enuresis or underlying distinct disorders were excluded. Data collection and analysis Two review authors independently classified studies and abstracted data from the included studies. We performed statistical analyses using a random-effects model and interpreted data according to the Cochrane Handbook for Systematic Reviews of Interventions. Main results We included 14 studies with 2966 randomized men across five comparisons. Desmopressin versus placebo: based on short-term follow-up (up to three months), desmopressin may have a similar effect on the number of nocturnal voids (mean difference (MD) -0.46, 95% confidence interval (CI) -0.94 to 0.01; low-quality evidence). We are uncertain about the effect of desmopressin on major adverse events at short-term follow-up (risk ratio (RR) 0.97, 95% CI 0.10 to 9.03; very low-quality evidence). For intermediate-term follow-up (three to 12 months), desmopressin may reduce the number of nocturnal voids in an appreciable number of participants (MD -0.85, 95% CI -1.17 to -0.53; low-quality evidence). Desmopressin may result in little or no difference in major adverse events at intermediate-term follow-up (RR 3.05, 95% CI 0.13 to 73.39; low-quality evidence). We found no evidence on quality of life. Subgroup analyses suggest a larger effect with oral, higher-dose formulations of desmopressin and in men with documented nocturnal polyuria. Desmopressin versus behavior modification: there were no data regarding the effect on the number of nocturnal voids, quality of life, or major adverse events. Desmopressin versus Alpha-Blocker: based on short-term follow-up, desmopressin likely has a similar effect on the number of nocturnal voids (MD 0.30, 95% CI -0.20 to 0.80; moderate-quality evidence) and quality of life (MD 0.00, 95% CI -0.35 to 0.35; moderate-quality evidence). There were no major adverse events in either study group. Desmopressin plus Alpha-Blocker versus Alpha-Blocker alone: based on short-term follow-up, combination therapy likely results in a small, unimportant reduction in the number of nocturnal voids (MD -0.47, 95% CI -0.73 to -0.21; moderate-quality evidence) and quality of life (MD -0.29, 95% CI -0.51 to -0.07; moderate-quality evidence). The risk of major adverse events may be similar (RR 0.30, 95% CI 0.01 to 7.32; low-quality evidence). Desmopressin plus Alpha-Blocker versus Alpha-Blocker plus an anticholinergic: based on short-term follow-up, combination therapy likely results in little or no difference in the number of nocturnal voids (MD -0.43, 95% CI -0.97 to 0.11; moderate-quality evidence). We found no evidence on quality of life. There were no major adverse events in either study group. Authors' conclusions Desmopressin may reduce the number of nocturnal voids in an appreciable number of participants compared to placebo in intermediate-term (three to 12 months) follow-up without increase in major adverse events. We found no evidence to compare its effects to behavior modification. The effect on the number of nocturnal voids is likely similar to that of Alpha-Blockers short-term with very infrequent major adverse events. There appears to be no added benefit in the combined use of desmopressin with an Alpha-Blocker or an anticholinergic. The findings of this review were limited by short-term follow-up, study limitations, and imprecision.
-
Desmopressin for treating nocturia in men.
The Cochrane database of systematic reviews, 2017Co-Authors: Jae Hung Jung, Caitlin J Bakker, Mark H Ebell, Philipp DahmAbstract:Nocturia is the bothersome symptom of awakening one or more times per night to void. Desmopressin is a commonly used medication for treating nocturia. To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. We performed a comprehensive search of medical literature with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017. We included randomized or quasi-randomized trials. Inclusion criteria were men with nocturia defined as one or more voids per night. Trials of children, adults with primary or secondary enuresis or underlying distinct disorders were excluded. Two review authors independently classified studies and abstracted data from the included studies. We performed statistical analyses using a random-effects model and interpreted data according to the Cochrane Handbook for Systematic Reviews of Interventions. We included 14 studies with 2966 randomized men across five comparisons. Desmopressin versus placebo: based on short-term follow-up (up to three months), desmopressin may have a similar effect on the number of nocturnal voids (mean difference (MD) -0.46, 95% confidence interval (CI) -0.94 to 0.01; low-quality evidence). We are uncertain about the effect of desmopressin on major adverse events at short-term follow-up (risk ratio (RR) 0.97, 95% CI 0.10 to 9.03; very low-quality evidence). For intermediate-term follow-up (three to 12 months), desmopressin may reduce the number of nocturnal voids in an appreciable number of participants (MD -0.85, 95% CI -1.17 to -0.53; low-quality evidence). Desmopressin may result in little or no difference in major adverse events at intermediate-term follow-up (RR 3.05, 95% CI 0.13 to 73.39; low-quality evidence). We found no evidence on quality of life. Subgroup analyses suggest a larger effect with oral, higher-dose formulations of desmopressin and in men with documented nocturnal polyuria. Desmopressin versus behavior modification: there were no data regarding the effect on the number of nocturnal voids, quality of life, or major adverse events. Desmopressin versus Alpha-Blocker: based on short-term follow-up, desmopressin likely has a similar effect on the number of nocturnal voids (MD 0.30, 95% CI -0.20 to 0.80; moderate-quality evidence) and quality of life (MD 0.00, 95% CI -0.35 to 0.35; moderate-quality evidence). There were no major adverse events in either study group. Desmopressin plus Alpha-Blocker versus Alpha-Blocker alone: based on short-term follow-up, combination therapy likely results in a small, unimportant reduction in the number of nocturnal voids (MD -0.47, 95% CI -0.73 to -0.21; moderate-quality evidence) and quality of life (MD -0.29, 95% CI -0.51 to -0.07; moderate-quality evidence). The risk of major adverse events may be similar (RR 0.30, 95% CI 0.01 to 7.32; low-quality evidence). Desmopressin plus Alpha-Blocker versus Alpha-Blocker plus an anticholinergic: based on short-term follow-up, combination therapy likely results in little or no difference in the number of nocturnal voids (MD -0.43, 95% CI -0.97 to 0.11; moderate-quality evidence). We found no evidence on quality of life. There were no major adverse events in either study group. Desmopressin may reduce the number of nocturnal voids in an appreciable number of participants compared to placebo in intermediate-term (three to 12 months) follow-up without increase in major adverse events. We found no evidence to compare its effects to behavior modification. The effect on the number of nocturnal voids is likely similar to that of Alpha-Blockers short-term with very infrequent major adverse events. There appears to be no added benefit in the combined use of desmopressin with an Alpha-Blocker or an anticholinergic. The findings of this review were limited by short-term follow-up, study limitations, and imprecision.
Richard C Rink - One of the best experts on this subject based on the ideXlab platform.
-
Alpha Blocker therapy for children with dysfunctional voiding and urinary retention.
The Journal of Urology, 2003Co-Authors: Mark P Cain, Paul F Austin, C D Anthony Herndon, Richard C RinkAbstract:ABSTRACTPurpose: Alpha Blocker therapy has been successfully used to decrease residual urine in children with complex neuropathic and nonneuropathic voiding dysfunction. We evaluated the safety and efficacy of using selective Alpha Blocker therapy for children with uncomplicated voiding dysfunction and underlying poor bladder emptying.Materials and Methods: A total of 55 patients with a mean age of 7.9 years presented with symptoms of urinary incontinence, urgency and urinary tract infection. All patients had increased post-void residual (PVR) on bladder ultrasound, with a mean residual volume of 65 ml (22% of age expected capacity). All patients were treated with doxazosin, a selective α-1 adrenergic antagonist, at dosages of 0.5 mg to 2.0 mg daily. Of the patients 38 were treated at presentation with a regimen of anticholinergics, timed voiding and antibiotic prophylaxis before initiating Alpha Blocker therapy. Patients were reevaluated with post-void ultrasound of the bladder 6 weeks after initiating a...
-
Alpha Blocker therapy for children with dysfunctional voiding and urinary retention.
The Journal of urology, 2003Co-Authors: Mark P Cain, Paul F Austin, C D Anthony Herndon, Richard C RinkAbstract:Alpha Blocker therapy has been successfully used to decrease residual urine in children with complex neuropathic and nonneuropathic voiding dysfunction. We evaluated the safety and efficacy of using selective Alpha Blocker therapy for children with uncomplicated voiding dysfunction and underlying poor bladder emptying. A total of 55 patients with a mean age of 7.9 years presented with symptoms of urinary incontinence, urgency and urinary tract infection. All patients had increased post-void residual (PVR) on bladder ultrasound, with a mean residual volume of 65 ml (22% of age expected capacity). All patients were treated with doxazosin, a selective Alpha-1 adrenergic antagonist, at dosages of 0.5 mg to 2.0 mg daily. Of the patients 38 were treated at presentation with a regimen of anticholinergics, timed voiding and antibiotic prophylaxis before initiating Alpha Blocker therapy. Patients were reevaluated with post-void ultrasound of the bladder 6 weeks after initiating Alpha Blocker therapy. After starting doxazosin average PVR decreased to 8 ml (p <0.0001), representing an 88% reduction in residual urine (or reduction to only 2.7% of age expected bladder capacity). Medication was discontinued in 2 patients due to minor side effects. Selective Alpha Blocker therapy appears to be effective for improving bladder emptying in children with an overactive bladder, wetting, recurrent infection and increased PVR urine. This therapy may be used as either a replacement or in addition to biofeedback in patients with urinary retention. Further investigation, including a prospective randomized trial of Alpha Blocker therapy in children with urinary tract dysfunction, is warranted based on the findings of our study.
-
Voiding Dysfunction Alpha Blocker THERAPY FOR CHILDREN WITH DYSFUNCTIONAL VOIDING AND URINARY RETENTION
2003Co-Authors: Mark P Cain, Paul F Austin, C D Anthony Herndon, Richard C RinkAbstract:Purpose: Alpha Blocker therapy has been successfully used to decrease residual urine in children with complex neuropathic and nonneuropathic voiding dysfunction. We evaluated the safety and efficacy of using selective Alpha Blocker therapy for children with uncomplicated voiding dysfunction and underlying poor bladder emptying. Materials and Methods: A total of 55 patients with a mean age of 7.9 years presented with symptoms of urinary incontinence, urgency and urinary tract infection. All patients had increased post-void residual (PVR) on bladder ultrasound, with a mean residual volume of 65 ml (22% of age expected capacity). All patients were treated with doxazosin, a selective -1 adrenergic antagonist, at dosages of 0.5 mg to 2.0 mg daily. Of the patients 38 were treated at presentation with a regimen of anticholinergics, timed voiding and antibiotic prophylaxis before initiating Alpha Blocker therapy. Patients were reevaluated with post-void ultrasound of the bladder 6 weeks after initiating Alpha Blocker therapy. Results: After starting doxazosin average PVR decreased to 8 ml (p 0.0001), representing an 88% reduction in residual urine (or reduction to only 2.7% of age expected bladder capacity). Medication was discontinued in 2 patients due to minor side effects. Conclusions: Selective Alpha Blocker therapy appears to be effective for improving bladder emptying in children with an overactive bladder, wetting, recurrent infection and increased PVR urine. This therapy may be used as either a replacement or in addition to biofeedback in patients with urinary retention. Further investigation, including a prospective randomized trial of Alpha Blocker therapy in children with urinary tract dysfunction, is warranted based on the findings of our study.
Marco H. Blanker - One of the best experts on this subject based on the ideXlab platform.
-
Discontinuation of Alpha-Blocker therapy in men with lower urinary tract symptoms : a systematic review and meta-analysis
BMJ open, 2019Co-Authors: Henk Van Der Worp, Petra Jellema, Ilse Hordijk, Yvonne Lisman-van Leeuwen, Lisa Korteschiel, Martijn G. Steffens, Marco H. BlankerAbstract:Objectives We aimed to synthesise the available data for the effect of stopping Alpha-Blocker therapy among men with lower urinary tract symptoms. The focus was on symptom, uroflowmetry and quality of life outcomes, but we also reviewed the adverse events (AEs) and the number of patients who restarted therapy. Data sources We searched MEDLINE/PubMed, EMBASE/Ovid and The Cochrane Central Register of Controlled Trials from inception to May 2018. Eligibility criteria We selected studies regardless of study design in which men were treated with an Alpha-Blocker for at least 3 months and in which the effects of Alpha-Blocker discontinuation were subsequently studied. Only controlled trials were used for the primary objective. Data extraction and synthesis Two reviewers independently extracted data and assessed the risk of bias for the controlled studies only using the Cochrane Collaboration’s tool for assessing risk of bias. Data were pooled using random-effects meta-analyses. Results We identified 10 studies (1081 participants) assessing the primary objective. Six studies (733 participants) assessed differences in AEs between continuation and discontinuation, and six studies (501 participants) reported the numbers of subjects that restarted treatment after discontinuation. No studies in primary care were identified. After discontinuing monotherapy, symptom scores increased and peak flow rates decreased at 3 and 6 months, but not at 12 months; however, neither parameter changed when Alpha-Blockers were stopped during combination therapy. Small differences in post-void residual volumes and quality of life scores were considered clinically irrelevant. We also found that 0%–49% of patients restarted after stopping Alpha-Blocker therapy and that AEs did not increase with discontinuation. Conclusions Discontinuing Alpha-Blocker monotherapy leads to a worsening compared with continuing therapy. Discontinuing the Alpha-Blocker after combination therapy had no significant effects on outcomes in either the short or long term. Discontinuation may be appropriate for the frail, elderly or those with concomitant illness or polypharmacy. However, studies in primary care are lacking. PROSPERO registration number CRD42016032648.
-
Patients' Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial
Drugs & aging, 2019Co-Authors: Malou Edelman, Petra Jellema, Eelko Hak, Petra Denig, Marco H. BlankerAbstract:The objective of this study was to gain insights into the attitudes of men with lower urinary tract symptoms towards deprescribing Alpha-Blockers and to assess their willingness to participate in a planned discontinuation trial. This was a cross-sectional questionnaire study. Men aged 30 years and older with lower urinary tract symptoms, who were first prescribed an Alpha-Blocker in 2015 or 2016, were selected from a population-based prescription database. We recorded lower urinary tract symptom severity (e.g., International Prostate Symptom Score and Overactive Bladder questionnaire) and patient characteristics (e.g., comorbidity and polypharmacy). The linguistically validated Dutch version of the revised Patients’ Attitudes Towards Deprescribing (rPATD) questionnaire was also used, to which we added ten specific questions on attitudes towards the deprescribing of Alpha-Blockers. Information about a future discontinuation trial on Alpha-Blockers was then provided and participants were asked to indicate if they would participate. We explored the explanatory factors for the willingness to participate by logistic regression analyses. Of the 1380 patients in the database, 421 were using an Alpha-Blocker, and 195 completed the questionnaire. Of these, 16 men were excluded because of indwelling catheter use or unknown indication. The mean age of the 179 participants was 69.4 (standard deviation 9.2) years. Most men were satisfied with their current therapy, but almost all (93%) were willing to stop the medicine at the request of a doctor. Therefore, most men (61%) were willing to participate in the proposed Alpha-Blocker discontinuation trial. Willingness to stop therapy was affected by patients’ perceptions of the appropriateness of Alpha-Blocker therapy and concerns about stopping that therapy. Although men who use Alpha-Blockers are generally satisfied with their current therapy, most will participate in a discontinuation trial.
-
symptom improvement and predictors associated with improvement after 6 weeks of Alpha Blocker therapy an exploratory single arm open label cohort study
PLOS ONE, 2019Co-Authors: Henk Van Der Worp, Martijn G. Steffens, Boudewijn J Kollen, Tom Vermist, Marco H. BlankerAbstract:Objectives Clinicians should not only know how many patients will benefit from Alpha-Blocker therapy but should also be able to identify who will benefit. We studied the changes in patient symptoms following Alpha-Blocker therapy and the predictors of symptom improvement in clinical practice. Design This was a single-arm, open-label observational cohort study with a 6-week follow-up. Setting Twenty-two pharmacies in the Netherlands. Participants Patients were eligible for inclusion if they attended a pharmacy with a new prescription for an Alpha-Blocker from a general practitioner or urologist. Primary and secondary outcomes Outcomes were assessed using the International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire Short Form (OAB-q SF), and Patient Global Impression of Improvement (PGI-I). Demographic, disease-related, and drug-related information were collected to identify predictors of symptom improvement. These predictors were then assessed by logistic and linear regression analyses of both the original data set and an imputed data set that accounted for the missing variables. Results During the study, 37% of patients with lower urinary tract symptoms perceived clear symptomatic improvement based on the results of the PGI-I. Improvement was more likely in those who still used Alpha-Blockers at the end of the 6-week study period and in those who used multiple medications. Although symptom scores decreased significantly on the IPSS and OAB-q SF, the only predictor of change was the pretreatment symptom severity. Conclusions Approximately one-third of our cohort perceived symptom improvement on Alpha-Blocker therapy. However, we identified no clear predictors of who might benefit from Alpha-Blocker treatment, indicating that Alpha-Blockers should still be prescribed on a trial basis.
Jae Hung Jung - One of the best experts on this subject based on the ideXlab platform.
-
desmopressin for treating nocturia in men
Cochrane Database of Systematic Reviews, 2017Co-Authors: Jae Hung Jung, Caitlin J Bakker, Mark H Ebell, Philipp DahmAbstract:Background Nocturia is the bothersome symptom of awakening one or more times per night to void. Desmopressin is a commonly used medication for treating nocturia. Objectives To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. Search methods We performed a comprehensive search of medical literature with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017. Selection criteria We included randomized or quasi-randomized trials. Inclusion criteria were men with nocturia defined as one or more voids per night. Trials of children, adults with primary or secondary enuresis or underlying distinct disorders were excluded. Data collection and analysis Two review authors independently classified studies and abstracted data from the included studies. We performed statistical analyses using a random-effects model and interpreted data according to the Cochrane Handbook for Systematic Reviews of Interventions. Main results We included 14 studies with 2966 randomized men across five comparisons. Desmopressin versus placebo: based on short-term follow-up (up to three months), desmopressin may have a similar effect on the number of nocturnal voids (mean difference (MD) -0.46, 95% confidence interval (CI) -0.94 to 0.01; low-quality evidence). We are uncertain about the effect of desmopressin on major adverse events at short-term follow-up (risk ratio (RR) 0.97, 95% CI 0.10 to 9.03; very low-quality evidence). For intermediate-term follow-up (three to 12 months), desmopressin may reduce the number of nocturnal voids in an appreciable number of participants (MD -0.85, 95% CI -1.17 to -0.53; low-quality evidence). Desmopressin may result in little or no difference in major adverse events at intermediate-term follow-up (RR 3.05, 95% CI 0.13 to 73.39; low-quality evidence). We found no evidence on quality of life. Subgroup analyses suggest a larger effect with oral, higher-dose formulations of desmopressin and in men with documented nocturnal polyuria. Desmopressin versus behavior modification: there were no data regarding the effect on the number of nocturnal voids, quality of life, or major adverse events. Desmopressin versus Alpha-Blocker: based on short-term follow-up, desmopressin likely has a similar effect on the number of nocturnal voids (MD 0.30, 95% CI -0.20 to 0.80; moderate-quality evidence) and quality of life (MD 0.00, 95% CI -0.35 to 0.35; moderate-quality evidence). There were no major adverse events in either study group. Desmopressin plus Alpha-Blocker versus Alpha-Blocker alone: based on short-term follow-up, combination therapy likely results in a small, unimportant reduction in the number of nocturnal voids (MD -0.47, 95% CI -0.73 to -0.21; moderate-quality evidence) and quality of life (MD -0.29, 95% CI -0.51 to -0.07; moderate-quality evidence). The risk of major adverse events may be similar (RR 0.30, 95% CI 0.01 to 7.32; low-quality evidence). Desmopressin plus Alpha-Blocker versus Alpha-Blocker plus an anticholinergic: based on short-term follow-up, combination therapy likely results in little or no difference in the number of nocturnal voids (MD -0.43, 95% CI -0.97 to 0.11; moderate-quality evidence). We found no evidence on quality of life. There were no major adverse events in either study group. Authors' conclusions Desmopressin may reduce the number of nocturnal voids in an appreciable number of participants compared to placebo in intermediate-term (three to 12 months) follow-up without increase in major adverse events. We found no evidence to compare its effects to behavior modification. The effect on the number of nocturnal voids is likely similar to that of Alpha-Blockers short-term with very infrequent major adverse events. There appears to be no added benefit in the combined use of desmopressin with an Alpha-Blocker or an anticholinergic. The findings of this review were limited by short-term follow-up, study limitations, and imprecision.
-
Desmopressin for treating nocturia in men.
The Cochrane database of systematic reviews, 2017Co-Authors: Jae Hung Jung, Caitlin J Bakker, Mark H Ebell, Philipp DahmAbstract:Nocturia is the bothersome symptom of awakening one or more times per night to void. Desmopressin is a commonly used medication for treating nocturia. To assess the effects of desmopressin as compared to other interventions in the treatment of nocturia in men. We performed a comprehensive search of medical literature with no restrictions on the language of publication or publication status. The date of the latest search of all databases was August 2017. We included randomized or quasi-randomized trials. Inclusion criteria were men with nocturia defined as one or more voids per night. Trials of children, adults with primary or secondary enuresis or underlying distinct disorders were excluded. Two review authors independently classified studies and abstracted data from the included studies. We performed statistical analyses using a random-effects model and interpreted data according to the Cochrane Handbook for Systematic Reviews of Interventions. We included 14 studies with 2966 randomized men across five comparisons. Desmopressin versus placebo: based on short-term follow-up (up to three months), desmopressin may have a similar effect on the number of nocturnal voids (mean difference (MD) -0.46, 95% confidence interval (CI) -0.94 to 0.01; low-quality evidence). We are uncertain about the effect of desmopressin on major adverse events at short-term follow-up (risk ratio (RR) 0.97, 95% CI 0.10 to 9.03; very low-quality evidence). For intermediate-term follow-up (three to 12 months), desmopressin may reduce the number of nocturnal voids in an appreciable number of participants (MD -0.85, 95% CI -1.17 to -0.53; low-quality evidence). Desmopressin may result in little or no difference in major adverse events at intermediate-term follow-up (RR 3.05, 95% CI 0.13 to 73.39; low-quality evidence). We found no evidence on quality of life. Subgroup analyses suggest a larger effect with oral, higher-dose formulations of desmopressin and in men with documented nocturnal polyuria. Desmopressin versus behavior modification: there were no data regarding the effect on the number of nocturnal voids, quality of life, or major adverse events. Desmopressin versus Alpha-Blocker: based on short-term follow-up, desmopressin likely has a similar effect on the number of nocturnal voids (MD 0.30, 95% CI -0.20 to 0.80; moderate-quality evidence) and quality of life (MD 0.00, 95% CI -0.35 to 0.35; moderate-quality evidence). There were no major adverse events in either study group. Desmopressin plus Alpha-Blocker versus Alpha-Blocker alone: based on short-term follow-up, combination therapy likely results in a small, unimportant reduction in the number of nocturnal voids (MD -0.47, 95% CI -0.73 to -0.21; moderate-quality evidence) and quality of life (MD -0.29, 95% CI -0.51 to -0.07; moderate-quality evidence). The risk of major adverse events may be similar (RR 0.30, 95% CI 0.01 to 7.32; low-quality evidence). Desmopressin plus Alpha-Blocker versus Alpha-Blocker plus an anticholinergic: based on short-term follow-up, combination therapy likely results in little or no difference in the number of nocturnal voids (MD -0.43, 95% CI -0.97 to 0.11; moderate-quality evidence). We found no evidence on quality of life. There were no major adverse events in either study group. Desmopressin may reduce the number of nocturnal voids in an appreciable number of participants compared to placebo in intermediate-term (three to 12 months) follow-up without increase in major adverse events. We found no evidence to compare its effects to behavior modification. The effect on the number of nocturnal voids is likely similar to that of Alpha-Blockers short-term with very infrequent major adverse events. There appears to be no added benefit in the combined use of desmopressin with an Alpha-Blocker or an anticholinergic. The findings of this review were limited by short-term follow-up, study limitations, and imprecision.
